Brief: Cantargia Presents Positive Results For Nadunolimab At Aacr 2023
14/03/2023 20:34
March 14 (Reuters) - Cantargia AB CANTA.ST :
* CANTARGIA PRESENTS POSITIVE RESULTS FOR NADUNOLIMAB AT
AACR 2023
INCLUDING NEW CLINICAL DATA IN PANCREATIC CANCER
* CANTARGIA - KEY FINDING IS THAT PANCREATIC CANCER
PATIENTS WITH
HIGH TUMOR LEVELS OF IL1RAP, BENEFIT MOST FROM NADUNOLIMAB
COMBINED WITH CHEMOTHERAPY
Source text for Eikon: ID:nWkr8vs2Mg
Further company coverage: CANTA.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML